Molecular Oncology
Volume 3, Issue 3 , Pages 204-213 , June 2009

Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells

  • Ulrike Olszewski

      Affiliations

    • Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria
    • Ludwig Boltzmann Cluster of Translational Oncology, A-1010 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Ludwig Boltzmann Cluster of Translational Oncology, c/o Balderichgasse 26/13, A-1170 Vienna, Austria. Tel./fax: +43 1 40400 6627.
    • ,
  • Gerhard Hamilton

      Affiliations

    • Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria
    • Ludwig Boltzmann Cluster of Translational Oncology, A-1010 Vienna, Austria

Received 15 October 2008 ,Accepted 23 January 2009.

References 

  1. Arthur JS, Cohen P. MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells. FEBS Lett. 2000;482:44–48
  2. Bianchini L, L'Allemain G, Pouyssegur J. The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors. J. Biol. Chem. 1997;272:271–279
  3. Bozou JC, Amar S, Vincent JP, Kitabgi P. Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol. Pharmacol. 1986;29:489–496
  4. Brahimi-Horn MC, Pouyssegur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem. 2007;43:165–178
  5. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973;248:6854–6861
  6. Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006;27:2445–2460
  7. Chiang Y, Chou CY, Hsu KF, Huang YF, Shen MR. EGF upregulates Na+/H+ exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness. J. Cell. Physiol. 2008;214:810–819
  8. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int. J. Cancer. 2001;92:503–509
  9. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426–4441
  10. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J. Pathol. 2008;214:283–293
  11. Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell. Biol. 2005;83:1–14
  12. Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin. Cancer Biol. 2008;18:330–337
  13. Fliegel L. The Na+/H+ exchanger isoform 1. Int. J. Biochem. Cell. Biol. 2005;37:33–37
  14. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br. J. Cancer. 2007;97:646–653
  15. Gesser B, Johansen C, Rasmussen MK, Funding AT, Otkjaer K, Kjellerup RB, et al. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J. Invest. Dermatol. 2007;127:2129–2137
  16. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134–1152
  17. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985;260:3440–3450
  18. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, et al Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. USA. 1993;90:65–69
  19. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 1997;280:802–812
  20. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene. 2001;20:1563–1569
  21. Herzig MC, Chapman WG, Sheridan A, Rake JB, Woynarowski JM. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res. 1999;19:213–219
  22. Iourgenko V, Zhang W, Mickanin C, Daly I, Jiang C, Hexham JM, et al Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc. Natl. Acad. Sci. USA. 2003;100:12147–12152
  23. Ishizuka J, Townsend CM, Thompson JC. Neurotensin regulates growth of human pancreatic cancer. Ann. Surg. 1993;217:439–445
  24. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, et al. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer. 1997;79:1787–1793
  25. Khaled AR, Moor AN, Li A, Kim K, Ferris DK, Muegge K, et al. Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol. Cell. Biol. 2001;21:7545–7557
  26. Kitabgi P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr. Opin. Drug Discov. Devel. 2002;5:764–776
  27. Kitabgi P. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides. 2006;27:2515–2522
  28. Kitabgi P, Carraway R, Leeman SE. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J. Biol. Chem. 1976;251:7053–7058
  29. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int. J. Oncol. 2003;22:765–771
  30. Li M, Zhang Y, Feurino LW, Wang H, Fisher WE, Brunicardi FC, et al. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci. 2008;99:733–737
  31. Liu G, Zhang Y, Bode AM, Ma WY, Dong Z. Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation. J. Biol. Chem. 2002;277:8810–8816
  32. Liu HF, Teng XC, Zheng JC, Chen G, Wang XW. Effect of NHE1 antisense gene transfection on the biological behavior of SGC-7901 human gastric carcinoma cells. World J. Gastroenterol. 2008;14:2162–2167
  33. Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, Pehamberger H, et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res. 2006;66:11888–11896
  34. Lugrin D, Vecchini F, Doulut S, Rodriguez M, Martinez J, Kitabgi P. Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur. J. Pharmacol. 1991;205:191–198
  35. Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking?. Cell. Signal. 2001;13:1–6
  36. McSwine RL, Li J, Villereal ML. Examination of the role for Ca2+ in regulation and phosphorylation of the Na+/H+ antiporter NHE1 via mitogen and hypertonic stimulation. J. Cell. Physiol. 1996;168:8–17
  37. Moellering RE, Black KC, Krishnamurty C, Baggett BK, Stafford P, Rain M, et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clin. Exp. Metastasis. 2008;25:411–425
  38. Nemeroff CB, Hernandez DE, Luttinger D, Kalivas PW, Prange AJ. Interactions of neurotensin with brain dopamine systems. Ann. N.Y. Acad. Sci. 1982;400:330–344
  39. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, et al. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays and essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 2000;14:2185–2197
  40. Reubi JC, Waser B, Schaer JC, Laissue JA. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int. J. Cancer. 1999;82:213–218
  41. Ryder NM, Guha S, Hines OJ, Reber HA, Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J. Cell. Physiol. 2001;186:53–64
  42. Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H, et al. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathways. Int. J. Cancer. 2008;123:1816–1823
  43. Shrode LD, Rubie EA, Woodgett JR, Grinstein S. Cytosolic alkalinization increases stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) activity and p38 mitogen-activated protein kinase activity by a calcium-independent mechanism. J. Biol. Chem. 1997;272:13653–13659
  44. Slepkov ER, Rainey JK, Sykes BD, Fliegel L. Structural and functional analysis of the Na+/H+ exchanger. Biochem. J. 2007;401:623–633
  45. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005;65:1027–1034
  46. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003;22:2788–2797
  47. Thomas RP, Hellmich MR, Townsend CM, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr. Rev. 2003;24:571–599
  48. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003;22:1313–1324
  49. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 1999;20:302–309
  50. Wang X, Wang Q, Ives KL, Evers BM. Cucurmin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin. Cancer Res. 2006;12:5346–5355
  51. Wenzl E, Sjaastad MD, Weintraub WH, Machen TE. Intracellular pH regulation in IEC-6 cells, a cryptlike intestinal cell line. Am. J. Physiol. 1989;257:G732–G740
  52. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell. Biol. 2002;22:2871–2881
  53. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12:375–391
  54. Yamada M, Ohata H, Momose K, Yamada M, Richelson E. Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Res. Commun. Mol. Pathol. Pharmacol. 1995;90:37–47
  55. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front. Biosci. 2005;10:853–865

PII: S1574-7891(09)00022-2

doi: 10.1016/j.molonc.2009.01.006

Molecular Oncology
Volume 3, Issue 3 , Pages 204-213 , June 2009

Article Tools

* Image Usage & Resolution